What is the address of DR. STEVEN VANHAEVRE - UROLOOG?

The registered office of DR. STEVEN VANHAEVRE - UROLOOG is located at Hanenbosweg 6, 1653 Beersel.

Is DR. STEVEN VANHAEVRE - UROLOOG still active?

Yes. According to the CBE (17 September 2026) DR. STEVEN VANHAEVRE - UROLOOG is active, legal situation “Normale toestand”, started on 20 January 2016.

Is DR. STEVEN VANHAEVRE - UROLOOG registered on Peppol?

Yes, DR. STEVEN VANHAEVRE - UROLOOG is registered on the Peppol network with ID 0208:0646800057.

What is the enterprise number of DR. STEVEN VANHAEVRE - UROLOOG?

The enterprise number of DR. STEVEN VANHAEVRE - UROLOOG is BE0646800057.

When was DR. STEVEN VANHAEVRE - UROLOOG founded?

DR. STEVEN VANHAEVRE - UROLOOG was founded on 20 January 2016.

Who are the directors of DR. STEVEN VANHAEVRE - UROLOOG?

According to the 2025 annual accounts, the directors of DR. STEVEN VANHAEVRE - UROLOOG are: Steven Vanhaevre.

Is DR. STEVEN VANHAEVRE - UROLOOG a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 20 January 2016; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did DR. STEVEN VANHAEVRE - UROLOOG make in 2025?

DR. STEVEN VANHAEVRE - UROLOOG recorded a loss after taxes of € 36,414 in financial year 2025.

What is the revenue of DR. STEVEN VANHAEVRE - UROLOOG?

As a small company, DR. STEVEN VANHAEVRE - UROLOOG is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 58,131.

DR. STEVEN VANHAEVRE - UROLOOG (Private Limited)

Dossier DR. STEVEN VANHAEVRE - UROLOOG, printed on 17 September 2026 from databakkes.be/en/0646800057/dr-steven-vanhaevre-uroloog. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

DR. STEVEN VANHAEVRE - UROLOOG from Beersel, company number BE0646800057, closed financial year 2025 with a result of € -36,414 after tax. For that financial year DR. STEVEN VANHAEVRE - UROLOOG recorded a gross margin of € 58,131 and equity of € 197,537. Compared with financial year 2024, the result moved from € 84,486 to € -36,414. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 6, 2026.

What it is worth Healthy

€ 197,537

▼ 29% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -36,414

▼ still € 84,486 profit in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 139,634

▲ 43% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € 178,937.

People and assets in 2025

Vehicles and equipment

€ 55,912

▼ 24% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 3 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 50,715

▼ 23% vs 2024

€ 15,351 is repaid this year. At this pace the long-term loan is gone in ≈ 3 years.

Owed to suppliers

€ 2,692

▼ 68% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 746

▼ 88% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 127,692 Gross margin 2022: € 127,692 First fiscal year in the series	€ 169,262 Gross margin 2023: € 169,262 ▲ 33% vs 2022 (€ 127,692) Favourable step	€ 203,229 Gross margin 2024: € 203,229 ▲ 20% vs 2023 (€ 169,262) Favourable step	€ 58,131 Gross margin 2025: € 58,131 ▼ 71% vs 2024 (€ 203,229) Unfavourable step	▼ 71%
Profit after taxes	€ 29,885 Profit after taxes 2022: € 29,885 First fiscal year in the series	€ 67,427 Profit after taxes 2023: € 67,427 ▲ 126% vs 2022 (€ 29,885) Favourable step	€ 84,486 Profit after taxes 2024: € 84,486 ▲ 25% vs 2023 (€ 67,427) Favourable step	€ -36,414 Profit after taxes 2025: € -36,414 ▼ € 120,901 vs 2024 (€ 84,486) Unfavourable step	▼ € 120,901
Equity	€ 301,343 Equity 2022: € 301,343 First fiscal year in the series	€ 368,770 Equity 2023: € 368,770 ▲ 22% vs 2022 (€ 301,343) Favourable step	€ 278,951 Equity 2024: € 278,951 ▼ 24% vs 2023 (€ 368,770) Unfavourable step	€ 197,537 Equity 2025: € 197,537 ▼ 29% vs 2024 (€ 278,951) Unfavourable step	▼ 29%
Total debts	€ 117,608 Total debts 2022: € 117,608 First fiscal year in the series	€ 45,007 Total debts 2023: € 45,007 ▼ 62% vs 2022 (€ 117,608) Favourable step	€ 244,706 Total debts 2024: € 244,706 ▲ € 199,700 vs 2023 (€ 45,007) Unfavourable step	€ 221,417 Total debts 2025: € 221,417 ▼ 10% vs 2024 (€ 244,706) Favourable step	▼ 10%
Cash	€ 125,271 Cash 2022: € 125,271 First fiscal year in the series	€ 172,176 Cash 2023: € 172,176 ▲ 37% vs 2022 (€ 125,271) Favourable step	€ 97,729 Cash 2024: € 97,729 ▼ 43% vs 2023 (€ 172,176) Unfavourable step	€ 139,634 Cash 2025: € 139,634 ▲ 43% vs 2024 (€ 97,729) Favourable step	▲ 43%
Retained profit	€ 282,743 Retained profit 2022: € 282,743 First fiscal year in the series	€ 350,170 Retained profit 2023: € 350,170 ▲ 24% vs 2022 (€ 282,743) Favourable step	€ 260,351 Retained profit 2024: € 260,351 ▼ 26% vs 2023 (€ 350,170) Unfavourable step	€ 178,937 Retained profit 2025: € 178,937 ▼ 31% vs 2024 (€ 260,351) Unfavourable step	▼ 31%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 0 Dividend 2023: € 0 Unchanged (€ 0) Unchanged	€ 174,305 Dividend 2024: € 174,305 Unchanged (€ 0) Unchanged	€ 45,000 Dividend 2025: € 45,000 ▼ 74% vs 2024 (€ 174,305) Unchanged	▼ 74%
Bank debt	€ 32,765 Bank debt 2022: € 32,765 First fiscal year in the series	€ 12,710 Bank debt 2023: € 12,710 ▼ 61% vs 2022 (€ 32,765) Favourable step	€ 65,486 Bank debt 2024: € 65,486 ▲ € 52,776 vs 2023 (€ 12,710) Unfavourable step	€ 50,715 Bank debt 2025: € 50,715 ▼ 23% vs 2024 (€ 65,486) Favourable step	▼ 23%
Balance sheet total	€ 418,952 Balance sheet total 2022: € 418,952 First fiscal year in the series	€ 413,776 Balance sheet total 2023: € 413,776 ▼ 1% vs 2022 (€ 418,952) Unchanged	€ 523,658 Balance sheet total 2024: € 523,658 ▲ 27% vs 2023 (€ 413,776) Unchanged	€ 418,954 Balance sheet total 2025: € 418,954 ▼ 20% vs 2024 (€ 523,658) Unchanged	▼ 20%

Key figures of DR. STEVEN VANHAEVRE - UROLOOG, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to DR. STEVEN VANHAEVRE - UROLOOG?

What happened at DR. STEVEN VANHAEVRE - UROLOOG in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 6, 2026 New annual accounts for financial year 2025: loss of € 36,414 (▼ € 120,901 vs 2024). filed late Source: NBB ↗
Jan 20, 2016 New establishment in Halle. KBO
2016 Steven Vanhaevre became a director. NBB
Jan 20, 2016 Start of the company according to the CBE. KBO

In short

From € 29,885 profit in 2022 to € 36,414 loss in 2025.

Paid € 59,411 in corporate taxes since 2022.

Best year ever: 2024, with € 84,486 profit.

Paid out € 219,305 in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at DR. STEVEN VANHAEVRE - UROLOOG? We notify you, reason included.

Follow DR. STEVEN VANHAEVRE - UROLOOG

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Steven Vanhaevre

DR. STEVEN VANHAEVRE - UROLOOG

Behind DR. STEVEN VANHAEVRE - UROLOOG is Steven Vanhaevre.

See the full network in the app

Directors

According to the 2025 annual accounts

Steven Vanhaevre

Director

since 2016

Establishments

Establishment units

Physical locations of this company

Registered office

Hanenbosweg 6

1653 Beersel

2.250.199.961

Ziekenhuislaan 100

1500 Halle

Active since 20 January 2016

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

VDLELIE

€ 202,374 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0646.800.057
VAT number: BE 0646.800.057
Registered office: Hanenbosweg 6, 1653 Beersel
Names & denominations: DR. STEVEN VANHAEVRE - UROLOOG · DR. STEVEN VANHAEVRE
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 20 January 2016
Peppol: Active · Active since 1 Jan 2001

View on CBE Public ↗ Annual accounts (NBB) ↗